.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,977,253

« Back to Dashboard
Patent 6,977,253 protects EQUETRO and is included in one NDA. There have been two Paragraph IV challenges on Equetro. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has one patent family member in one country.

Summary for Patent: 6,977,253

Title: Methods for the treatment of bipolar disorder using carbamazepine
Abstract:Carbamazepine, in extended release form, is useful in the treatment of patients suffering from bipolar disorder. In order to minimize the time it takes to reach efficacy, carbamazepine, in extended release form, can be administered to the patient at an initial daily dose which is then increased in daily increments until clinical efficacy is achieved.
Inventor(s): Kalali; Amir H. (San Diego, CA), Tulloch; Simon J. (Gaithersburg, MD)
Assignee: Shire Pharmaceutical Development Inc. (Rockville, MD)
Application Number:10/848,383
Patent Claim Types:
see list of patent claims
Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 8th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-001Dec 10, 2004RXNo6,977,253► subscribe THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-002Dec 10, 2004RXNo6,977,253► subscribe THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
Validus Pharms Inc
EQUETRO
carbamazepine
CAPSULE, EXTENDED RELEASE;ORAL021710-003Dec 10, 2004RXYes6,977,253► subscribe THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,977,253

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2452588► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc